Your SlideShare is downloading. ×
0
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Idenix and its Solution to Hepatitis B
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Idenix and its Solution to Hepatitis B

270

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
270
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
13
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Idenix and its Solution to Hepatitis B By: Jeff Walter
  • 2. Company’s Mission & Overview
    • Founded in May, 1998
    • “ Engaged in the discovery, development, and commercialization of innovative treatments for human infecetious diseases”
    • Research and drug programs for Hepatitis B, Hepatitis C, and HIV/AIDS
  • 3. Company’s Overview Continued
    • Small company: 143 employees
    • Began trading common stock July, 2004
    • Offered 5.8 million shares @ $14.00/share
    • Novartis chief private investor = 5.4 million shares privately placed
    • Ticker symbol: IDIX
    • Current trade price: $8.39
  • 4. Research/Drug Programs & Products
  • 5. Telbivudine/Ldt Overview
    • Drug being developed to treat Hepatitis B
    • Currently in Phase III of Clinical Evaluation
      • Phase III programs involves 1200 patients from 120 clinical research sites in Asia, Europe, and North America
      • Evaluating safety and effectiveness of Ldt vs. standard treatments in patients w/liver disease
  • 6. Ldt Overview Continued
    • Potent, selective, and specific nucleoside antiviral
    • 3 Goals:
      • Improve clinical effectiveness - supress HBV replication and subside the liver disease
      • Ensure drug is safe with little or no side effects
      • Offer in convenient oral dose treatments such as tablets
  • 7. Hepatitis B (HBV) Overview
    • Hepatitis itself is any form of inflammation of the liver
    • HBV is most serious type of viral hepatitis
    • Currently over 300 million carriers worldwide
    • Virus transmitted by contact wit blood or body fluids of infected person - same way as HIV but 50 - 100 times more infectious
  • 8. HBV Overview Continued
    • Different types of transmission
      • Blood or blood products - needles via unsafe injections or transfusions
      • Blood born cases such as mother to child via pregnancy
      • Child to child transmission
      • Sexual Contact
  • 9. HBV Symptoms
    • 30% of infected do not report any symptoms associated with disease
    • 70% remaining experience flu-like symptoms: body aches, low-grade fever, and mild abdominal pain
    • Virus can cause acute disease
      • Symptoms: yellowing of skin and eyes, dark urine, extreme fatigue, nausea, and vomiting
  • 10. HBV is Fatal
    • Victims of HBV can develop a chronic infection - cannot get rid of the disease
      • Result: years later will develop cirrhosis of the liver or liver cancer
      • Disease kills approximately 1 million people/year
  • 11. Questions

×